SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)
Majem Tarruella, Margarita (Institut d'Investigació Biomèdica Sant Pau)
García-Martínez, Elena (Hospital General Universitario Morales Meseguer (Múrcia))
Martinez Garcia, Maria (Institut Hospital del Mar d'Investigacions Mèdiques)
Muñoz Couselo, Eva (Vall d'Hebron Institut d'Oncologia)
Rodriguez-Abreu, Delvys (Complejo Hospitalario Universitario Insular Materno Infantil (Las Palmas de Gran Canaria))
Alvarez, R. (Hospital Virgen de la Salud (Toledo))
Arance, Ana (Hospital Clínic i Provincial de Barcelona)
Berrocal, Alfonso (Hospital General Universitario de Valencia)
de La Cruz-Merino, Luis (Universidad de Sevilla)
Lopez-Martin, Jose A. (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12))
Universitat Autònoma de Barcelona

Date:	2020
Abstract:	The use of immune checkpoint inhibitors has emerged as an effective treatment option for patients with several tumor types. By increasing the activity of the immune system, they can induce inflammatory side effects, which are often termed immune-related adverse events. These are pathophysiologically unique toxicities, compared with those from other anticancer therapies. In addition, the spectrum of the target organs is very broad. Immune-inflammatory adverse events can be life threatening. Prompt diagnosis and pharmacological intervention are instrumental to avoid progression to severe manifestations. Consequently, clinicians require new skills to successfully diagnose and manage these events. These SEOM guidelines have been developed with the consensus of ten medical oncologists. Relevant studies published in peer-review journals were used for the guideline elaboration. The Infectious Diseases Society of America grading system was used to assign levels of evidence and grades of recommendation.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Immunotherapy ; IrAEs ; Toxicity
Published in:	Clinical & translational oncology, Vol. 22 Núm. 2 (january 2020) , p. 213-222, ISSN 1699-3055

DOI: 10.1007/s12094-019-02273-x
PMID: 31993963

10 p, 1.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles